rasagiline mesylate

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2017
02420022017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Cytochrome P-450 (CYP) enzymes and P-glycoprotein (P-gp) play an important role in the oral bioavailability and first-pass… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2015
2015
Intranasal thermosensitive gel for rasagiline mesylate (RM) was developed for effective treatment of Parkinson's disease… (More)
Is this relevant?
2014
2014
A precise and rapid reverse phase HPLC method has been developed for the estimation of Rasagiline Mesylate in bulk drug under… (More)
  • figure 2
  • figure 3
  • figure 4
  • table 1
  • table 3
Is this relevant?
2013
2013
The main goal of the present study was to evaluate applicability of the different model substrates, namely orodispersible films… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
A simple, rapid and sensitive reverse-phase liquid chromatographic method is developed and validated for estimation of rasagiline… (More)
  • table I
  • figure 1
  • figure 2
  • table II
  • table III
Is this relevant?
2012
2012
Microencapsulation of rasagiline mesylate (RM) into PLGA microspheres was performed by method A (O/W emulsion) and method B (W/O… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 3
Is this relevant?
2011
2011
This is the first report on the efficacy of a new controlled release system developed for rasagiline mesylate (RM) in a rotenone… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
2009
2009
In the present study, a reverse phase high performance liquid chromatographic method was developed and validated for the… (More)
  • figure 1
  • figure 2
  • table 2
  • table 4
  • table 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
  • Archives of neurology
  • 2004
BACKGROUND Treatment with rasagiline mesylate, an irreversible monoamine oxidase type B inhibitor, improves symptoms of early… (More)
Is this relevant?
2004
2004
Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor. This… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?